Gwan Gyu Song1,2, Young Ho Lee3. 1. Department of Rheumatology, Korea University College of Medicine, Seoul, Korea. lyhcgh@korea.ac.kr. 2. Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, Seoul, 02841, Korea. lyhcgh@korea.ac.kr. 3. Department of Rheumatology, Korea University College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: Tofacitinib and apremilast have shown considerable efficacy in placebo-controlled trials of active psoriatic arthritis, but the relative efficacy and safety remain unclear because of a lack of head-to-head comparisons. OBJECTIVE: The aim of this study was to assess the relative efficacy and safety of tofacitinib and apremilast at different doses in patients with active psoriatic arthritis. METHOD: We performed a Bayesian network meta-analysis to combine evidence from randomized controlled trials for examination of the efficacy and safety of tofacitinib 10 mg, tofacitinib 5 mg, apremilast 30 mg, and apremilast 20 mg in psoriatic arthritis. RESULTS: Eight randomized controlled trials including 3086 patients met the inclusion criteria. There were ten pairwise comparisons including six direct comparisons of five interventions. All the interventions achieved a significant American College of Rheumatology 20 response compared with placebo. Tofacitinib 10 mg and apremilast 30 mg were among the most effective treatments for active psoriatic arthritis, followed by tofacitinib 5 mg, and apremilast 20 mg. The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that tofacitinib 10 mg had the highest probability of being the best treatment in terms of the American College of Rheumatology 20 response rate (SUCRA = 0.785). This was followed by apremilast 30 mg (SUCRA = 0.670), tofacitinib 5 mg (SUCRA = 0.596), apremilast 20 mg (SUCRA = 0.448), and placebo (SUCRA = 0.001). We observed no significant differences in the incidence of serious adverse events after treatment with tofacitinib 10 mg, apremilast 30 mg, tofacitinib 5 mg, apremilast 20 mg, or placebo. CONCLUSIONS: In patients with active psoriatic arthritis, tofacitinib 10 mg and apremilast 30 mg were the most efficacious interventions and were not associated with a significant risk of serious adverse events.
BACKGROUND:Tofacitinib and apremilast have shown considerable efficacy in placebo-controlled trials of active psoriatic arthritis, but the relative efficacy and safety remain unclear because of a lack of head-to-head comparisons. OBJECTIVE: The aim of this study was to assess the relative efficacy and safety of tofacitinib and apremilast at different doses in patients with active psoriatic arthritis. METHOD: We performed a Bayesian network meta-analysis to combine evidence from randomized controlled trials for examination of the efficacy and safety of tofacitinib 10 mg, tofacitinib 5 mg, apremilast 30 mg, and apremilast 20 mg in psoriatic arthritis. RESULTS: Eight randomized controlled trials including 3086 patients met the inclusion criteria. There were ten pairwise comparisons including six direct comparisons of five interventions. All the interventions achieved a significant American College of Rheumatology 20 response compared with placebo. Tofacitinib 10 mg and apremilast 30 mg were among the most effective treatments for active psoriatic arthritis, followed by tofacitinib 5 mg, and apremilast 20 mg. The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that tofacitinib 10 mg had the highest probability of being the best treatment in terms of the American College of Rheumatology 20 response rate (SUCRA = 0.785). This was followed by apremilast 30 mg (SUCRA = 0.670), tofacitinib 5 mg (SUCRA = 0.596), apremilast 20 mg (SUCRA = 0.448), and placebo (SUCRA = 0.001). We observed no significant differences in the incidence of serious adverse events after treatment with tofacitinib 10 mg, apremilast 30 mg, tofacitinib 5 mg, apremilast 20 mg, or placebo. CONCLUSIONS: In patients with active psoriatic arthritis, tofacitinib 10 mg and apremilast 30 mg were the most efficacious interventions and were not associated with a significant risk of serious adverse events.
Authors: Jill E Chrencik; Akshay Patny; Iris K Leung; Brian Korniski; Thomas L Emmons; Troii Hall; Robin A Weinberg; Jennifer A Gormley; Jennifer M Williams; Jacqueline E Day; Jeffrey L Hirsch; James R Kiefer; Joseph W Leone; H David Fischer; Cynthia D Sommers; Horng-Chih Huang; E J Jacobsen; Ruth E Tenbrink; Alfredo G Tomasselli; Timothy E Benson Journal: J Mol Biol Date: 2010-05-15 Impact factor: 5.469
Authors: Zoe Ash; Cécile Gaujoux-Viala; Laure Gossec; Elizabeth M A Hensor; Oliver FitzGerald; Kevin Winthrop; Désirée van der Heijde; Paul Emery; Josef S Smolen; Helena Marzo-Ortega Journal: Ann Rheum Dis Date: 2011-07-28 Impact factor: 19.103
Authors: Dafna Gladman; William Rigby; Valderilio F Azevedo; Frank Behrens; Ricardo Blanco; Andrzej Kaszuba; Elizabeth Kudlacz; Cunshan Wang; Sujatha Menon; Thijs Hendrikx; Keith S Kanik Journal: N Engl J Med Date: 2017-10-19 Impact factor: 91.245
Authors: Philip Mease; Stephen Hall; Oliver FitzGerald; Désirée van der Heijde; Joseph F Merola; Francisco Avila-Zapata; Dorota Cieślak; Daniela Graham; Cunshan Wang; Sujatha Menon; Thijs Hendrikx; Keith S Kanik Journal: N Engl J Med Date: 2017-10-19 Impact factor: 91.245
Authors: Paul S Changelian; Mark E Flanagan; Douglas J Ball; Craig R Kent; Kelly S Magnuson; William H Martin; Bonnie J Rizzuti; Perry S Sawyer; Bret D Perry; William H Brissette; Sandra P McCurdy; Elizabeth M Kudlacz; Maryrose J Conklyn; Eileen A Elliott; Erika R Koslov; Michael B Fisher; Timothy J Strelevitz; Kwansik Yoon; David A Whipple; Jianmin Sun; Michael J Munchhof; John L Doty; Jeffrey M Casavant; Todd A Blumenkopf; Michael Hines; Matthew F Brown; Brett M Lillie; Chakrapani Subramanyam; Chang Shang-Poa; Anthony J Milici; Gretchen E Beckius; James D Moyer; Chunyan Su; Thasia G Woodworth; Anderson S Gaweco; Chan R Beals; Bruce H Littman; Douglas A Fisher; James F Smith; Panayiotis Zagouras; Holly A Magna; Mary J Saltarelli; Kimberly S Johnson; Linda F Nelms; Shelley G Des Etages; Lisa S Hayes; Thomas T Kawabata; Deborah Finco-Kent; Deanna L Baker; Michael Larson; Ming-Sing Si; Ricardo Paniagua; John Higgins; Bari Holm; Bruce Reitz; Yong-Jie Zhou; Randall E Morris; John J O'Shea; Dominic C Borie Journal: Science Date: 2003-10-31 Impact factor: 47.728
Authors: L Gossec; J S Smolen; C Gaujoux-Viala; Z Ash; H Marzo-Ortega; D van der Heijde; O FitzGerald; D Aletaha; P Balint; D Boumpas; J Braun; F C Breedveld; G Burmester; J D Cañete; M de Wit; H Dagfinrud; K de Vlam; M Dougados; P Helliwell; A Kavanaugh; T K Kvien; R Landewé; T Luger; M Maccarone; D McGonagle; N McHugh; I B McInnes; C Ritchlin; J Sieper; P P Tak; G Valesini; J Vencovsky; K L Winthrop; A Zink; P Emery Journal: Ann Rheum Dis Date: 2011-09-27 Impact factor: 19.103
Authors: Dafna D Gladman; Ana-Maria Orbai; Juan Gomez-Reino; Stacey Chang-Douglass; Emanuele Leoncini; Hannah E Burton; Keith S Kanik; Ana Belen Romero; Joseph C Cappelleri; Ming-Ann Hsu Journal: Curr Ther Res Clin Exp Date: 2020-08-12